17. Multiple system atrophy
107 clinical trials,   153 drugs   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04431713
(ClinicalTrials.gov)
September 16, 202029/5/2020Exenatide Once-weekly as a Treatment for Multiple System AtrophyAn Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System AtrophyMultiple System AtrophyDrug: Exenatide Pen Injector [Bydureon]University College, LondonNULLRecruiting30 Years80 YearsAll50Phase 2United Kingdom
2EUCTR2020-000122-26-GB
(EUCTR)
11/05/202006/04/2020Exenatide once-weekly as a treatment for Multiple System Atrophy.A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy - Exenatide once-weekly as a treatment for Multiple System Atrophy. Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders
Trade Name: Bydureon
Product Name: Bydureon
INN or Proposed INN: Exenatide
University College London (UCL)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2United Kingdom